A5102778021- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Immunodeficiency and Autoimmune Disorders
- Inflammasome and immune disorders
- Childhood Cancer Survivors' Quality of Life
- Human Health and Disease
- Systemic Lupus Erythematosus Research
- Child and Adolescent Health
- Rheumatoid Arthritis Research and Therapies
- Salivary Gland Disorders and Functions
- Kawasaki Disease and Coronary Complications
- Heterotopic Ossification and Related Conditions
- Ocular Diseases and Behçet’s Syndrome
- Dermatological and COVID-19 studies
- Blood disorders and treatments
- Inflammatory Myopathies and Dermatomyositis
- Connective tissue disorders research
- Bone Tumor Diagnosis and Treatments
- Hemophilia Treatment and Research
- Spondyloarthritis Studies and Treatments
- Otitis Media and Relapsing Polychondritis
- Tuberculosis Research and Epidemiology
- Family and Disability Support Research
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders
VA Nasonova Scientific Research Institute of Rheumatology
2014-2022
NOVA Scientific (United States)
2019
Russian Academy of Sciences
2001-2013
Academy of Medical Sciences
2001
Introduction: Systemic juvenile arthritis -a rare chronic disease.Registerit's an important tool to monitor the effectiveness and safety of GIBP.Objectives: Our aim was study features drug therapy children with systemic idiopathic (sJIA) Methods: We conducted a retrospective data analysis included in Register sJIA cases, for period from 2002 2015 Results: The indicators 384 are studied.Prior diagnosis verification, all patients were prescribed intake antipyretic agents, 98%...
Objective: Our aim was to study features of the drug therapy children with systemic juvenile idiopathic arthritis (sJIA). Methods: We conducted a retrospective data analysis included in Register sJIA cases, for period from 2002 2015. Results: The indicators 384 are studied. Prior diagnosis verification, all patients were prescribed intake antipyretic agents, 98% — antibiotics. After diagnosis, non-steroidal anti-inflammatory drugs (NSAIDs) intaken by 282 (73.4%) patients: diclofenac sodium...
Objective : Our aim was to study demographic and clinical characteristics of patients with systemic juvenile idiopathic arthritis (sJIA), timing diagnosis routing the children after onset disease according All-Russian Register Union Pediatricians Russia. Methods Retrospective (1998–2015) analyzing indicators from 384 sJIA. Results The majority live in Central Volga Federal Districts — 157 (40.9%) 68 (17.7%) patients, respectively. ratio girls boys is 1.25:1; 281 (73.2%) got sick under age 5....
The introduction of tocilizumab — a drug that blocks interleukin 6 into the practice pediatric rheumatologists is an important achievement in treatment systemic juvenile arthritis (SJA). Objective : Our aim was to identify factors associated with level response and safety children SJA. Methods: We examined SJA (n =49) who received from November 2009 June 2014. therapy efficiency evaluated according ACR pedi criteria. Results: initial positive found 100% patients. At end five-year monitoring...
Systemic lupus erythematosus (SLE) with its onset in childhood or adolescence is a significant problem the practice of pediatricians and rheumatologists due to diagnostic difficulties, clinical features, greater likelihood unfavorable prognosis. About 20% SLE patients fall ill at age 18 years. Only 13% juvenile-onset have drug-free remission adulthood lower quality life than population controls. The paper discusses latest international guidelines for diagnosis, monitoring, treatment children...
Aim to analyze demographic data, clinical features and results of laboratory instrumental examinations in children with primary secondary Sjögren syndrome (SS).The study included all consequently patients, who hospitalized the pediatric department V.A. Nasonova Scientific Research Institute Rheumatology from January 2013 December 2018, which verified diagnosis SS.The SS was established 30 among whom there were only 5 (16.7%) boys, ratio boys girls 1:5. According examination, following...
Tocilizumab (TCZ) is one of the biological agents that are most commonly used in treatment juvenile idiopathic arthritis (JIA), especially its systemic variant. The development neutropenia, which associated with use TCZ and mechanism action, requires a detailed study. Based on analysis their own results comparison latter data available literature, authors analyze aspects neutropenia during therapy. Objective: to all cases polyarticular (pJIA) (sJIA) variants disease. Subjects methods....
<h3>Background</h3> Interleukin-1 inhibitor Canakinumab (a humanized anti- Il-1β monoclonal antibody) is gaining wider use in Russian clinical practice recently for treatment of auto-inflammatory diseases (AIDs). Experience with systemic juvenile idiopathic arthritis (SoJIA), considered as AIDs, being accumulated first and second line <i>biologic agents</i> therapy. In Russia was initially marketed 2011 cryopyrin-associated periodic syndromes (CAPS), 2013 – SoJIA. <h3>Objectives</h3> To...
<h3>Background</h3> Treatment of juvenile onset rheumatic diseases (RD) is an ongoing problem because the more aggressive disease course and various clinical manifestations than adult-onset RD. Since main symptoms may overlap between well-known RD, in some cases path to diagnosis search for optimal therapy takes longer, especially patients pre-adolescence adolescence. <h3>Objectives</h3> We described a rare case one boy with RD who presented initially severe dermatomyositis sequential...
<h3>Background</h3> Systemic lupus erythematosus is a complex autoimmune disorder characterized by multisystem involvement, including the nervous system, which elevate damage and mortality. The investigation of neuropsychiatric involvement in childhood-onset SLE (cSLE) important real clinical practice to improve prognosis. <h3>Objectives</h3> aim this study was assess manifestations (NM) cSLE one single center. <h3>Methods</h3> included all pts with who undergoing in-patient treatment our...
Background In recent years the use of Biologics (B) at management systemic lupus erythematosus including with juvenile onset (jSLE) has increased. Belimumab (BEL) became first approved B for SLE. The rituximab (RTM), despite status “of label”, remains relevant in a number patients (pts) poor response to standard therapy and presence life-threatening conditions. However, real clinical practice increase slowly, part, due uncertainty over which pts should be treated what stage disease, safety....
Background Children and adolescents who suffered from the rare polygenic autoinflammatory disease such as multifocal non-bacterial osteomyelitis (NBO) can stay without specialized care for long time. Currently we don’t have standardized treatment these patients. Administration of Biologics (B) established on opportunity to diagnose juvenile idiopathic arthritis (JIA) or ankylosing spondylitis (JAS) in relation combination bone lesions with and/or axial skeleton damage. Objectives To describe...
Background: Biological agents (BA), especially TNF inhibitors, are high efficacy options for current therapy patients (pts) with juvenile idiopathic arthritis (JIA). They successfully used not only the but also JIA-associated uveitis, however, development of uveitis de novo in pts treated BA is a well-established paradoxical phenomenon. Objectives: to evaluate frequency new onset ( no -) occurring under JIA pts, establish clinical features, which may be associated such effects. Methods:...
Methods In prospective study were included 45 pts(19b/26g) with sJIA refractory to conventional treatment, who was treated by TCZ from 9 months 54 months. At baseline mean age of 6.25(2.0-17.8)yrs; disease duration 4.5(0.315.9)yrs. used as the 1 B in 28 pts, 2 – 12, 3 5. 37.8% pts previously received B:TNF-ingibitors-17, abatacept–2, rituximab–3. 41 pts(91.1%) had arthritis at baseline. Systemic features observed 40(88.9%) pts. Mean number systemic manifestations(NSM) 2.82 (1.5;6). MAS...
The paper describes a patient with refractory systemic juvenile arthritis treated tocilizumab (TCZ). Specific features of therapeutic response in real clinical practice, aspects of individual TCZ safety the development of macrophage activation syndrome and concurrent therapy are discussed.
<h3>Background</h3> Macrophage activation syndrome (MAS) is a potentially fatal and hard to manage complication of rheumatic diseases (RD). MAS early diagnosis real challenge, whiles timely adequate therapy has the paramount importance for reduction associated mortality. <h3>Objectives</h3> To analyze clinical laboratory parameters, therapeutic regimens outcomes in pediatric patients with RD. <h3>Methods</h3> Retrospective analysis 35 RD last 5 years. <h3>Results</h3> was diagnosed pts...
<h3>Background</h3> Human autoinflammatory diseases (HAIDS) are a group of rare heterogeneous genetically determined disorders characterized by periodic fever, attacks inflammatory and rheumatic-like symptoms without autoimmune marks or infection. Clinical features the systemic onset juvenile arthritis (soJA) has similar so it9s belonging to HAIDS is discussed. In addition, large number evidence indicates pathogenesis soJA be closely associated with abnormalities in innate immune system....
<h3>Background</h3> Biologic agents have improved the possibility of treatment juvenile idiopathic arthritis (JIA). Infliximab has longest history using and despite <i>off-label</i> status was administrated from 2004. Etanercept is available in Russia 2009. Unfortunately some patients do not respond to them or side effects. Drug survival a general marker success treatment, as it depends on drug efficacy its <h3>Objectives</h3> To evaluate (continuation rates drug) (BA) JIA (pts),...
<h3>Background</h3> It is known that Tocilizumab (TCZ) effective option in systemic Juvenile idiopathic arthritis (sJIA). NNZ had “off label” status for children Russia till December 2011, but with Ethics Committee approvement it used clinical practice most seriously affected sJIA patients (Pts). <h3>Objectives</h3> To analyzed effects of TCZ on activity and other disease features Ptswith active sJIA, who were received our clinic from Nov 2009 to Jan 2012. <h3>Methods</h3> was indicate 23...
<h3>Background</h3> Biological agents (BA) are high efficacy options for current therapy patients (pts) with juvenile idiopathic arthritis (JIA). They successfully used not only the but also uveitis, psoriasis and inflammatory bowel disease (IBD). However, paradoxical induction of these conditions in pts treated BA is a well-established phenomenon. <h3>Objectives</h3> To evaluate frequency new onset or IBD occurring under JIA pts, to establish clinical features, which may be associated...
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report results cross-cultural adaptation and validation parent patient versions JAMAR Russian language. reading comprehension questionnaire was tested 10 JIA parents patients. Each participating centre asked to collect demographic, clinical data 100 consecutive...
<h3>Background</h3> Fibrodysplasia Ossificans Progressiva (FOP), also known as a "second skeleton disease" is extremely rare (1: 2000000) and disabling genetic disorder, caused by mutation of ACVR1 gene, bone morphogenetic protein receptor. Among medical specialties there are no certain, capable to provide not only diagnostics, but all maintenance (assessment monitoring extent damages, the differentiated drug treatment, rehabilitation, contact with adjacent experts). It would be reasonable...
<h3>Background</h3> Sometimes Crohn's disease (CD) manifests initially with rheumatological symptoms. Therefore, there's an important for a rheumatologist to recognize this pathology correctly and timely. <h3>Objectives</h3> To present cases of CD, referred V.A. Nasonova Research Institute Rheumatology. <h3>Methods</h3> Case series 7 pts (5 boys, 2 girls) initial condition who developed CD. All were subjected standard examination. CD diagnosis was suggested by confirmed in gastroenterology...